Keeping a keen eye on the therapeutic potential of rapamycin-an immunomodulator 1st approved as a prophylactic against organ rejection. Two new pilots show that: 1) it didn’t penetrate the BBB but improved inflammatory biomarkers and 2) fatigue, cognition in #MECFS www.nature.com/articles/s43...
Rapamycin treatment for Alzheimer’s disease and related dementias: a pilot phase 1 clinical trial - Communications Medicine
Gonzales et al. conducted an open-label phase 1 clinical trial of rapamycin for mild cognitive impairment and dementia due to Alzheimer’s disease. Rapamycin is not detected in cerebrospinal fluid befo...
nature.com